Aged Care Insite Australia's number one aged care news source
Hoping to appeal to millions of needle-phobic diabetics, drugmakers Sanofi and Mannkind have launched Afrezza, an insulin that's inhaled, rather than injected.
Afrezza was approved by the US Food and Drug Administration last June for patients with either Type 1 or 2 diabetes, to be used along with other medicines, diet and exercise.
Sanofi SA, a major player in the huge diabetes treatment market, then licensed Afrezza's worldwide marketing rights from Mannkind Corp of Valencia, California, which developed Afrezza.
"This is an alternative for those patients who are not willing to inject insulin" or to increase the number of shots per day, Stefan Schwarz, Sanofi's head of US marketing for Afrezza, said.
That's a lot of patients. More than 30 million Americans are estimated to have diabetes, an incurable hormonal disorder in which the body either doesn't properly respond to or doesn't produce enough insulin, which converts sugar from food into energy.
As excess sugar accumulates, it damages blood vessels and vital organs and inhibits healing. The disease is a leading cause of amputations, blindness and other serious complications.
Meanwhile, a 2013 study in the journal Diabetes Care found that half of adults taking pills for diabetes delay the start of insulin use for five or more years to avoid injecting it in their stomach or elsewhere one or more times a day.
However, many patients don't have their diabetes under good control, and insulin usually does that better than pills.
Still, an inhaled insulin launched in 2006 by Pfizer Inc, Exubera, was pulled from the market in 2007 because of disappointing sales.
Schwarz noted that the formulation of Afrezza - different from Exubera's - disburses it widely in the lungs so it enters the bloodstream rapidly and hits peak levels in just 15 minutes.
"You can basically plan around your day, rather than planning around your insulin," Schwarz said.
By comparison, injected insulin peaks in the blood in about 90 minutes, so patients must inject it well before each meal and know in advance what and how much they'll be eating to calculate the dose.
Do you have an idea for a story?
Email [email protected]
Get the news delivered straight to your inbox
Receive the top stories in our weekly newsletter Sign up now